Cetuximab, Trametinib, Cft1946
Crc, Atc, Melanoma, Solid Tumors, Nsclc
Active Not Recruiting
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
―